Mitigare® for the Prevention of Gout Flares in Adults: What You Need to Know

Mitigare for the prevention of gout flares

Gout is a painful form of inflammatory arthritis1 caused by a condition called hyperuricemia. Hyperuricemia happens when there is too much uric acid in the body. When there is too much uric acid in the body, uric acid crystals can build up in the joints, causing pain and swelling.

Our bodies manufacture uric acid as they metabolize purines, which are found in many foods and drinks.1 Causing painful swelling and redness in one or more joints, gout flares often occur first in the big toe.2 Gout flares may also show up in the heels, instep, ankles, knees, elbows, hips, thumbs and fingers.1

To prevent gout flares, the Task Force Panel (TFP) of the American College of Rheumatology recommends oral colchicine as a first-line option.3 The TFP also recommends as a first-line option (although with a lower evidence grade than for colchicine) the use of low-dose NSAIDs (such as naproxen 250 mg, orally, twice a day) with proton pump inhibitor therapy, or other effective suppression therapy for peptic-ulcer disease and its complications, where indicated.3 In its evaluation of colchicine for gout flare prevention, the TFP specifically recommended low-dose colchicine (0.5 mg or 0.6 mg, orally, once or twice a day).4

 

Colchicine may help prevent flares in adults with gout

Fortunately for adults with gout, medicines to help prevent gout flares are available. One such medicine that your doctor may prescribe is colchicine. Colchicine, which is derived from a plant sometimes called the autumn crocus or meadow saffron, was discovered centuries ago.5 Colchicine is the active ingredient in a prescription medicine called Mitigare® (colchicine) 0.6 mg capsules. Mitigare® is FDA-approved to help prevent gout flares in adults.6

 

Colchicine: Evidence-based efficacy

Colchicine, the active ingredient in Mitigare®, can help prevent gout flares in adults.6

 

Fewer total flares with colchicine 0.6 mg than with placebo6

Mit Gout Flares Gout Blog 6

43 patients starting allopurinol were randomized to receive colchicine 0.6 mg or placebo for up to 6 months. The chart shows the mean number of acute gout flares at the 0-3 and 3-6 month time periods, and overall.6

 

Colchicine 0.6 mg therapy has been shown to be safe in adult patients who are candidates for colchicine therapy

In a six-month study of prophylactic use in adult patients with recurrent gout, colchicine 0.6 mg was shown to be well tolerated.6 The most commonly reported adverse reactions with colchicine are gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain.7 Colchicine may not be right for all adult patients; consult with your doctor about other medications you are currently prescribed and review the complete safety information available in the Package Insert.

The safety and effectiveness of Mitigare for acute treatment of gout flares during prophylaxis has not been studied. Mitigare is not an analgesic medication and should not be used to treat pain from other causes.

 

Colchicine is once again affordable to more people

In 2009, the Food and Drug Administration (FDA) approved the first branded version of colchicine. Although all other colchicine formulations, including the formulation for Mitigare®, had been sold for many years, the FDA removed them from the market after the 2009 approval. The FDA removed these products because they had not gone through the FDA’s formal drug review process. As a result, patients who tried to refill their colchicine prescriptions found that their previous colchicine medications were no longer available. The only prescription option available was a newly-branded colchicine product offered by a pharmaceutical company that charged $5 per pill—a price 50 times higher than that of previously available colchicine pills.8

Today, West-Ward Pharmaceuticals Corp. offers colchicine capsules under the brand name Mitigare®. West-Ward also introduced an authorized generic colchicine capsule immediately following the FDA’s approval of the branded form, Mitigare®. West-Ward’s colchicine 0.6 mg capsule is the only colchicine therapy available in capsule form and was the first authorized generic form of this therapy.

 

Consider the capsule for the prevention of gout flares

Mitigare®and its authorized generic are the only colchicine medications for the prevention of gout flares in adults that are available in capsule form. The Mitigare® True Blue Savings program provides the first fill free of charge and offers $5 refills for eligible patients.*

*Free fill up to a $65 value; $5 refill up to a $50 value. Click here for Terms & Conditions and eligibility requirements.

 

Color matters

The Mitigare® capsule and its authorized generic come in a distinctive two-tone blue capsule, which is easy to identify. According to the FDA, older adults who take more than one medicine should be able to tell them apart by size, shape, color and form (tablet or capsule).9

Mit Pills Efficacy

 

Important Safety Information

Consult with your doctor about other medications you are currently prescribed. Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given Mitigare®.

Fatal overdoses have been reported with colchicine in adults and children. Keep Mitigare® out of the reach of children. Blood dyscrasias such as myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, and aplastic anemia have been reported with colchicine used in therapeutic doses. Monitor for toxicity and if present consider temporary interruption or discontinuation of colchicine.

 

NOTE:  This article was not written by a medical professional and is not intended to substitute the guidance of a physician. These are not West-Ward’s recommendations for gout flare prevention, but rather facts and data collected from various reliable medical sources. For a full list of resources and their attributing links, see below.

References

  1. Centers for Disease Control. Gout. http://www.cdc.gov/arthritis/basics/gout.html. Accessed 6/24/17.
  2. Mayo Clinic Staff. Gout. http://www.mayoclinic.org/diseases-conditions/gout/basics/symptoms/CON-20019400. Accessed 6/24/17.
  3. Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology Guidelines for Management of Gout. Part 2: Therapy and Antiinflammatory Prophylaxis of Acute Gouty Arthritis. Arthritis Care Res (Hoboken). 2012;64:1447-1451 and 1456-1459.
  4. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology Guidelines for Management of Gout. Part 1: Systematic Nonpharmacologic and Pharmacologic Therapeutic Approaches to Hyperuricemia. Arthritis Care Res (Hoboken). 2012;64: 1431–1446.
  5. The New York Times. Gout Overview; Treatment: Acute Gout Attack. http://www.nytimes.com/health/guides/disease/acute-gouty-arthritis/treatment:-acute-gout-attack.html?print=1. Accessed 6/24/2017.
  6. Borstad GC, Bryant LR, Abel MP,Scroggie DA, Harris MD, Alloway JA. Colchicine prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004; 31:2429-2432
  7. Mitigare® (colchicine) capsules [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals Corp: 2014.
  8. Court allows generic colchicine to enter market. Rheumatology News. January 28, 2015. http://www.rheumatologynews.com/?id=8821&tx_ttnews%5Btt_news%5D=375553&cHash=864c0fa58eba19db0a8a7c6d630b47e6. Accessed 6/6/2017.
  9. U.S. Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for Industry: Safety Considerations for Product Design to Minimize Medication Errors. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm331810.pdf. Accessed 6/6/2017.

Important Safety Information for Mitigare® (colchicine) 0.6 mg capsules

  • Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given Mitigare®.
  • Fatal overdoses have been reported with colchicine in adults and children. Keep Mitigare® out of the reach of children.
  • Blood dyscrasias such as myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, and aplastic anemia have been reported with colchicine used in therapeutic doses.
  • Monitor for toxicity and if present consider temporary interruption or discontinuation of colchicine.
  • Drug interaction with dual P-gp and CYP3A4 inhibitors: Co-administration of colchicine with dual P-gp and CYP3A4 inhibitors has resulted in life-threatening interactions and death.
  • Neuromuscular toxicity and rhabdomyolysis may occur with chronic treatment with colchicine in therapeutic doses, especially in combination with other drugs known to cause this effect. Patients with impaired renal function and elderly patients (including those with normal renal and hepatic function) are at increased risk. Consider temporary interruption or discontinuation of Mitigare®.
  • The most commonly reported adverse reactions with colchicine are gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain.

Indication

Mitigare® is indicated for prophylaxis of gout flares in adults. The safety and effectiveness of Mitigare for acute treatment of gout flares during prophylaxis has not been studied.

Mitigare® is not an analgesic medication and should not be used to treat pain from other causes.

For Full Prescribing Information please CLICK HERE and for Medication Guide CLICK HERE.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Manufactured by: West-Ward Columbus Inc., Columbus, OH 43228

Important Safety Information for Mitigare® (colchicine) 0.6 mg capsules

  • Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given Mitigare®.
  • Fatal overdoses have been reported with colchicine in adults and children. Keep Mitigare® out of the reach of children.